WEBULL
WebtradeDownload

How Eye Trial Success At Merck (MRK) Has Changed Its Investment Story

Simply Wall St · 2d ago
  • Merck reported topline data from the pivotal Phase 2b/3 BRUNELLO trial showing its investigational antibody remigromig matched ranibizumab on 52 week visual acuity outcomes in adults with diabetic macular edema, with both remigromig doses generally well tolerated but with higher rates of certain ocular adverse events.
  • The BRUNELLO readout highlights Merck’s effort to build a retinal disease franchise beyond oncology and may broaden its future revenue mix across ophthalmology indications such as DME, neovascular age related macular degeneration and retinal vein occlusion.
  • We will now look at how Merck's investment narrative could be affected by remigromig's Phase 2b/3 non inferiority result in DME.
Spot potential Merck peers building ophthalmology and retinal treatment pipelines by scanning our curated list of 38 healthcare AI stocks shaping the next wave of data driven drug development.

Merck Investment Narrative Recap

To own Merck, you need to believe management can convert a broad late stage portfolio into new revenue streams before KEYTRUDA’s eventual loss of exclusivity bites, while managing pricing pressure, tariffs and weaker GARDASIL demand in China. The remigromig data fits this story as pipeline proof, but does not change the near term earnings swing factors.

The biggest short term catalyst still sits in oncology and newer launches like WINREVAIR and CAPVAXIVE, not in ophthalmology. The key risk remains pipeline execution falling short of offsetting pricing and competition. BRUNELLO’s mixed safety profile reinforces that Merck’s growth plan depends on many shots on goal, with uneven outcomes along the way.

The WINREVAIR label update in pulmonary arterial hypertension is the most relevant recent announcement in this context. It shows Merck trying to diversify meaningful revenue drivers beyond KEYTRUDA, similar to what the retinal push with remigromig is aiming for in eye disease. HYPERION’s data are now embedded in the U.S. label, which supports real world adoption decisions.

For you as a shareholder, that creates a pattern. WINREVAIR, CAPVAXIVE, remigromig and the MK 8748 program in retinal disease all speak to the same operational goal: turning a tripled late phase pipeline into more than 20 new growth drivers. Execution risk is high, but every positive label or pivotal readout shortens the list of things that still need to go right.

Merck's narrative projects US$75.1b revenue and US$22.4b earnings by 2029. This assumes 4.1% yearly revenue growth and an earnings increase of about US$19.2b from US$3.2b today.

Uncover why Merck's fair value indicates that Merck is currently priced roughly in line with its valuation.

NYSE:MRK 1-Year Stock Price Chart
NYSE:MRK 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the most optimistic analysts already assumed Merck could reach about US$82.1b in revenue and US$30.2b in earnings by 2029, far above the consensus US$75.1b and US$22.4b. Those forecasts were set before the remigromig BRUNELLO result. You now get to judge whether this retinal update nudges that bullish story closer or further away.

Explore 6 other Merck fair value estimates, including one that suggests as much as 59% upside from the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For More Merck Investment Ideas?

If the Merck story has you thinking about portfolio balance, it can help to line it up against other listed businesses using the Simply Wall St Screener. You can quickly sort companies by balance sheet strength, valuation or income profile and see where Merck fits in your broader watchlist.

  • For stability first investors, consider screening for companies with resilient finances using our list of solid balance sheet and fundamentals (23 results) and see which businesses pair healthy leverage with consistent fundamentals.
  • If value is your priority, you can scan for potentially mispriced opportunities by running the 30 high quality undervalued stocks and compare their metrics with what you see at Merck.
  • Income focused portfolios might benefit from lining up cash return potential across markets by checking the 7 dividend fortresses and assessing how those yields and payout profiles sit alongside Merck's prospects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.